Rare disease market access – Launching orphan drugs in secondary markets: the Nordic and MENA regions

Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?

In this webinar,  our Global Market Access team compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy?

In an earlier rare disease market access webinar, we explored the challenges facing orphan medicines entering key European markets. Here, we explore some of the markets that can be neglected or forgotten about by Global teams. The rare markets if you like.

Our Global Market Access experts explore contrasting regions to showcase the significant differences between international markets when it comes to:

• Overall and rare disease patient populations
• Access inequalities
• Time to diagnosis
• Access to innovation timelines
• Healthcare funding
• Health technology assessment frameworks

Robert Taaffe (Consultant – Global Market Access) presents his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates.

Michelle James (Associate Consultant – Global Market Access) showcases market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway.

Clare Foy (Director – Global Market Access) leads our discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy.